Cardiovascular · Small interfering RNA (siRNA)

Olpasiran

Olpasiran is an injectable small interfering RNA that lowers lipoprotein(a), a genetically determined cardiovascular risk factor, by more than 95% at higher doses. Its Phase 3 outcomes trial is ongoing.

Not yet approvedPhase 3 cardiovascular outcomes trial ongoing; Phase 2 showed near-complete Lp(a) lowering

Not yet approved: Not approved for any use. The drug is still being tested in clinical trials. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperAmgen · Amgen pipeline
Drug typeSmall interfering RNA (siRNA)
TargetLPA gene (apolipoprotein(a)) mRNA
MechanismSilences the LPA gene's messenger RNA in the liver, sharply reducing production of apolipoprotein(a) and lowering lipoprotein(a)
Other namesAMG 890

Key points

  • Olpasiran uses RNA interference to block production of apolipoprotein(a), the protein that defines lipoprotein(a) [Lp(a)].
  • In the 281-patient Phase 2 OCEAN(a)-DOSE trial, doses of 75 mg or more every 12 weeks lowered Lp(a) by about 97% to 101% versus placebo at 36 weeks.
  • Lp(a) lowering persisted after treatment stopped: about 40% to 50% close to a year after the last dose in the extension period.
  • OCEAN(a)-Outcomes, a Phase 3 trial of 7,297 patients, is testing whether this reduces heart attacks and coronary deaths. ClinicalTrials.gov lists an estimated primary completion of March 2028.
  • The failure of pelacarsen's Lp(a)HORIZON outcomes trial in 2026 makes the OCEAN(a)-Outcomes result a critical test of the whole Lp(a) strategy.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Elevated lipoprotein(a) with cardiovascular disease
OCEAN(a)-Outcomes is active, not recruiting; OCEAN(a)-PreEvent, a primary-prevention outcomes trial, is recruiting (registry).
Phase 36
3 active · 3 completed
52.4% eventual approval
Phase 3 → application: 57.8%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What olpasiran is

Olpasiran is a small interfering RNA (siRNA), a short double-stranded RNA molecule that harnesses the cell's natural RNA-interference machinery to destroy a specific messenger RNA. Olpasiran targets the RNA from the LPA gene, which carries instructions for making apolipoprotein(a), the protein that defines lipoprotein(a), or Lp(a). With less apolipoprotein(a), the liver releases far less Lp(a) into the blood. Olpasiran is developed by Amgen and is given as an injection under the skin every 12 weeks or less often.

Why Lp(a) matters

Lp(a) levels are largely inherited and barely respond to diet or exercise. Genetic studies, including a 2009 analysis in the New England Journal of Medicine, found that variants raising Lp(a) are associated with markedly higher risk of coronary disease. That genetic evidence is the main reason several companies are developing Lp(a)-lowering drugs. See What Is Genomics?

Clinical evidence

Phase 2: OCEAN(a)-DOSE

OCEAN(a)-DOSE enrolled 281 patients with established cardiovascular disease and a median Lp(a) of 260.3 nmol/L, most already taking statins. At 36 weeks, the placebo-adjusted mean changes in Lp(a) were:

Dose Placebo-adjusted change in Lp(a)
10 mg every 12 weeks −70.5%
75 mg every 12 weeks −97.4%
225 mg every 12 weeks −101.1%
225 mg every 24 weeks −100.5%

Source: O'Donoghue et al., NEJM (2022). Reductions slightly above 100% reflect placebo adjustment, since Lp(a) rose by a mean of 3.6% in the placebo group.

Durability

In the extension period, reported in the Journal of the American College of Cardiology in 2024, Lp(a) stayed substantially lower after dosing stopped. Patients who had received 75 mg or more every 12 weeks had roughly 40% to 50% lower Lp(a) close to a year after their last dose. No new safety concerns were identified during the off-treatment follow-up.

Phase 3: outcomes trials

Trial Population Primary endpoint Size Status (registry)
OCEAN(a)-Outcomes Established atherosclerotic cardiovascular disease and elevated Lp(a) Time to coronary heart disease death, heart attack, or urgent coronary revascularization 7,297 Active, not recruiting; estimated primary completion March 2028
OCEAN(a)-PreEvent People without a prior major cardiovascular event (primary prevention) Same coronary composite Estimated 11,000 Recruiting

Scientific perspective

Olpasiran has demonstrated what it was designed to do: near-complete, durable suppression of Lp(a). What it has not yet shown is that this prevents heart attacks. That is a question only an outcomes trial can answer.

In September 2026 the answer became much less certain. Pelacarsen, an antisense drug that lowered Lp(a) by about 78%, did not reduce major cardiovascular events in the 8,323-patient Lp(a)HORIZON trial. See the pelacarsen profile. There are real differences between the drugs and trials, any of which could matter:

  • Depth of lowering. Olpasiran's Phase 2 reductions exceeded 95% at the doses being tested, compared with about 78% for pelacarsen in its outcomes trial.
  • Endpoint. OCEAN(a)-Outcomes uses a coronary composite: coronary death, heart attack, or urgent coronary revascularization.
  • Population and duration. Trial populations, background therapy, and follow-up times differ.

None of these differences guarantees a different result. The pelacarsen outcome shows that strong genetic evidence for a risk factor does not by itself guarantee that lowering it with a drug will prevent events. This is a central caution in What Is a Primary Clinical Trial Endpoint?

Development perspective

  • Regulatory status: olpasiran has no FDA approval and, to our knowledge, has not been submitted for approval. Approval for cardiovascular risk reduction would be expected to depend on a positive outcomes trial.
  • Key catalyst: the OCEAN(a)-Outcomes readout. The registry estimates primary completion in March 2028. Sponsors' estimated dates often move, and changes will be logged on this page.
  • Historical benchmark: for an average Phase 3 program, 57.8% have historically advanced to an application and about 52% to approval. This benchmark predates the pelacarsen result and does not account for it. It describes programs in general, not this drug.

Competitive context

Lp(a) is now one of the most closely watched targets in cardiovascular drug development, with antisense (pelacarsen), siRNA (lepodisiran, zerlasiran), and oral (muvalaplin) approaches all in clinical testing. After Lp(a)HORIZON, investors and clinicians are likely to treat each remaining outcomes trial as a test of the Lp(a) hypothesis itself, not only of the individual drug.

Development timeline

  1. Jul 28, 2020OCEAN(a)-DOSE Phase 2 dose-finding trial begins. Registry
  2. Nov 6, 2022OCEAN(a)-DOSE results published: placebo-adjusted Lp(a) reductions of up to about 101% at 36 weeks. Peer-reviewed
  3. Dec 14, 2022OCEAN(a)-Outcomes Phase 3 cardiovascular outcomes trial begins. Registry
  4. Aug 27, 2024Extension results published: Lp(a) remained about 40% to 50% lower close to a year after the last dose at 75 mg or more. Peer-reviewed
  5. Aug 22, 2025OCEAN(a)-PreEvent, a primary-prevention outcomes trial with an estimated 11,000 participants, begins. Registry
  6. Sep 4, 2026Read-across: pelacarsen, a different Lp(a)-lowering drug, misses the primary endpoint of its Phase 3 outcomes trial. Company-reported

What could change the outlook

  • The OCEAN(a)-Outcomes result, the decisive test of whether olpasiran reduces coronary events. The registry lists estimated primary completion in March 2028.
  • Whether the deeper Lp(a) lowering achieved by olpasiran, compared with pelacarsen, translates into a different clinical outcome.
  • Any changes to OCEAN(a)-Outcomes or OCEAN(a)-PreEvent in the registry, such as endpoint, size, or timing amendments, following the pelacarsen result.
  • Long-term safety data, given the drug's prolonged effect after dosing.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Olpasiran. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedNov 3, 2026

    AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

    Olpasiran (AMG 890) • Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver. • The OCEAN(a)-Outcomes trial, a Phase 3 secondary prevention CV outcomes study, is ongoing in patients with established atherosclerotic CV...

    Company
    Amgen
    Source
    SEC Form 8-K · Financial results
  2. Quarterly reportCompany-reportedAug 4, 2026

    AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

    Olpasiran (AMG 890) • Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver. • The OCEAN(a)-Outcomes trial, a Phase 3 secondary prevention CV outcomes study, is ongoing in patients with established atherosclerotic CV...

    Company
    Amgen
    Source
    SEC Form 8-K · Financial results

All Olpasiran disclosures in Pipeline News

Clinical trials

10 registered trials list Olpasiran as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Elevated lipoprotein(a) with cardiovascular disease

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07136012
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
Phase 3Recruiting11,000 (est.)Oct 20, 2031 (est.)No
NCT05581303
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Phase 3Active, not recruiting7,297Mar 31, 2028 (est.)No
OCEAN(a)-CCTA · NCT07293260
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Phase 3Recruiting406 (est.)Jun 15, 2028 (est.)No
NCT04270760
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Phase 2Completed281Dec 27, 2021Yes
2 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT03626662
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
Phase 1Completed79Apr 18, 2023Yes
NCT04987320
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)
Phase 1Completed24Nov 12, 2021Yes

Clinical pharmacology and supporting studies

4 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT05489614
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
Phase 1Completed33Oct 24, 2023No
NCT06411860
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
Phase 1Completed32Nov 29, 2024No
NCT05481411
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
Phase 1Completed25Apr 5, 2023No
NCT07079267
Olpasiran Expanded Access Program
N/AAVAILABLE——No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. O'Donoghue ML, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. New England Journal of Medicine. 2022;387(20):1855–1864.Peer-reviewed
  2. O'Donoghue ML, et al. The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-DOSE extension period results. Journal of the American College of Cardiology. 2024;84(9):790–797.Peer-reviewed
  3. ClinicalTrials.gov. OCEAN(a)-Outcomes (NCT05581303).Registry
  4. ClinicalTrials.gov. OCEAN(a)-PreEvent (NCT07136012).Registry
  5. Clarke R, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New England Journal of Medicine. 2009;361(26):2518–2528.Peer-reviewed
  6. American Heart Association Newsroom. Lp(a) HORIZON trial results (AHA Scientific Sessions 2026).Scientific meeting
  7. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.